Related Experiment Videos

Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and

Osama A Ibrahim1, Mark E Dunlap

  • 1Case Western Reserve University and Louis B. Stokes Veterans Affairs Medical Center, Research Service, 151W 10701 East Boulevard, Cleveland, OH 44106, USA.

Current Heart Failure Reports
|July 23, 2005
PubMed

Insights

Newer pharmacologic therapies for heart failure (HF) aim for global neurohormonal blockade to reverse ventricular remodeling. Promising agents and recent trials offer potential for improved HF management and reduced mortality.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Despite advances with ACE inhibitors and beta-blockers, heart failure (HF) morbidity and mortality remain high.
  • There is a continuous need for novel therapeutic agents to improve outcomes in HF patients.
  • Current research focuses on comprehensive neurohormonal blockade and alternative targets to address HF pathophysiology.

Purpose of the Study:

  • To review recent pharmacologic advances in heart failure (HF) management.
  • To discuss clinical trials evaluating new HF therapies.
  • To highlight promising agents with potential for incremental benefit in HF.

Main Methods:

  • Review of recent clinical trials in heart failure pharmacotherapy.
  • Analysis of novel therapeutic targets beyond traditional neurohormonal blockade.
  • Discussion of emerging drug classes and their potential impact on HF treatment.

Main Results:

  • Several new therapeutic approaches have demonstrated benefit or show promise in HF.
  • Targeting neurohormonal systems aims to reduce or reverse ventricular remodeling.
  • Alternative strategies focusing on myocardial metabolism and vasculature are under investigation.

Conclusions:

  • Newer pharmacologic agents offer potential for improved heart failure management.
  • Global neurohormonal blockade and novel targets are key areas of research.
  • Ongoing trials and emerging therapies may significantly impact HF treatment paradigms.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...